For Noor ul Fajar, the reality of living with Type 1 diabetes is measured not just in blood glucose readings, but in the reliability of a specific medical supply. Having relied on Apidra for the past 15 years, Fajar recently found herself facing a terrifying prospect: a dwindling supply with no clear path to replenishment. As she noted, "I am a Type 1 diabetic. I have been relying on Apidra for the past 15 years. I only have one day left; after that, I can’t use it because it is currently unavailable anywhere in Pakistan." Her experience is mirrored by others, such as Rameen Amir, who has utilized Apidra SoloStar for 13 years. For Amir, the stakes are existential: "This insulin is like oxygen for me; I cannot survive without it."
These individual stories of panic are unfolding against a backdrop of a massive public health challenge. Pakistan currently faces a staggering reality, with approximately 34 million people living with diabetes. This figure places the country as having the third-highest number of diabetes patients globally, trailing only India and China. In such a vast population, the disruption of a single, widely used medication creates a ripple effect that is felt in households across the nation, turning a logistical supply issue into a profound humanitarian concern.
A shortage of Apidra insulin has been reported in Lahore and across Pakistan, raising concerns among Type 1 diabetes patients who rely on the medication to manage their condition. #SamaaTV https://t.co/pYjYyArPu1
On October 20, 2026, the Pakistani government moved to address the growing public outcry. Both the Health Ministry and the Drug Regulatory Authority of Pakistan (DRAP) issued formal statements denying reports of a widespread insulin shortage. The authorities sought to draw a clear distinction between a total system failure and the specific unavailability of one product. According to officials, the insulin glulisine brand Apidra, manufactured by Sanofi, has become unavailable due to international supply constraints. The government maintains that other insulin formulations remain available nationwide, urging citizens not to conflate the absence of one brand with a collapse of the entire supply chain.
The government’s clarification came in the wake of a surge of social media activity.
The government’s clarification came in the wake of a surge of social media activity. Patients, feeling the pressure of their vanishing supplies, began posting videos online documenting their inability to source Apidra. These digital testimonials served as a catalyst for the national conversation, forcing the issue into the public eye and compelling the Health Ministry and DRAP to clarify their positions on October 20, 2026. The videos highlighted a growing sense of desperation among those who have spent years perfecting their treatment regimens with a specific product.
Thousands of patients living with Diabetes are reportedly facing difficulties in Pakistan due to the shortage of an essential insulin, Apidra. According to reports, the insulin brand that many diabetic patients have relied on for years is AI-generated image, for reference only. https://t.co/kqIGJ3liQw
As the availability of Apidra has plummeted, patient advocates have issued urgent warnings against the dangers of turning to the black market. The fear is that in their desperation, patients might resort to purchasing counterfeit or improperly stored medication, which could pose risks far greater than the inconvenience of switching brands. Advocates are instead urging patients to consult with medical professionals to find safe, approved alternatives, such as NovoRapid or Humalog, rather than attempting to bypass regulated channels.
Beyond the immediate crisis, the government is now under pressure to ensure that such a bottleneck does not occur again. On October 20, 2026, authorities indicated they are actively exploring long-term solutions to bolster the nation's insulin security. These plans include the potential for importing insulin from Russia and a broader initiative to promote and incentivize local manufacturing. By reducing reliance on specific international suppliers, the government hopes to insulate the Pakistani healthcare system from the volatility of global supply chains, ensuring that patients like Fajar and Amir can access the life-sustaining treatment they require without the constant fear of sudden, unexplained shortages.
The health ministry spokesperson said patients who have been prescribed Apidra “should consult their attending healthcare provider prior to modifying their regimen”. https://t.co/JxVAcQOSpK